With 0 sell/buy ratio, Melinta Therapeutics, Inc. (NASDAQ:MLNT) experienced more insider buying than insider selling over the last twelve months. Could this be a sign for outside investors to start buying as well? MLNT corporate insiders offloaded no shares in that period when buyers snapped up 23,370,000 shares.
Cammarata Sue gathered a total of 4 thousand shares of Melinta Therapeutics, Inc. (MLNT) at average share price of $5. This insider trade in the company took place on 05/29/2018. The total for the purchase was set at $20 thousand. After this transaction, the Chief Medical Officer account balance stood at 4 thousand shares. The stock lost -67.4 percent since that insider purchase. On 05/29/2018, Vatera Healthcare Partners Llc, Director, 10% Owner, purchased 23.26 million shares at a price per share of $5. This added 116.29 million shares to the insider’s fortune and the stock saw a -67.4 percent retreat in value since the news became public. This transaction left 32.62 million shares in the Director, 10% Owner account.
On 05/29/2018, Wechsler Daniel Mark performed a purchase transaction worth $250 thousand. This purchase at $5 each has added 50 thousand shares into the insider’s portfolio position. Meanwhile, shares have recorded -67.4 percent decrease since the transaction was reported. The insider now is left with 50 thousand shares remaining in the account. Duffy Erin, who performs the Chief Scientific Officer job, bought 4 thousand shares for $20 thousand. The acquisition occurred on 05/29/2018 was priced at $5 per share. The share price plunged -67.4 percent since the reporting date. Duffy Erin now left with a stake of 4 thousand MLNT stock worth $6.52 thousand after the insider buying.
The 12-month median price target for Melinta Therapeutics, Inc. (MLNT) assigned by the analysts stands at $13.5, which represents a return potential of 728.22 percent when compared to the closing price of the stock of $1.63 on Tuesday, February 12. The lowest price target for the stock is $6 — slightly more than 268.1 percent from MLNT’s current share price. The stock will probably climb 587.12 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $15 price as 12-month high target. This represents a whopping 820.25 percent increase from where shares are trading today.
On momentum oscillators front, ‘RSI’ has touched 64.29 on daily chart, which may remain a cause for concern. If the price breaks below $1.46 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $1.75 mark may result into a pull-back move towards $1.86 level. The stock is currently hovering around the first support level of $1.55. Below this, the next support is placed in the zone of $1.46. Till the time, the MLNT stock trades above this level, bulls have nothing to fear.
Shares of Melinta Therapeutics, Inc. (MLNT) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry MLNT operates in has an average P/E of 87.76. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 1.49 on the Price-to-Sales ratio. Compare this with the industry average P/S of 50.73. 50.8 percent is the gross profit margin for Melinta Therapeutics, Inc. and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.
On 12th of February, Melinta Therapeutics, Inc. (NASDAQ:MLNT) shares ended lower after a volatile session. The shares dropped -0.07 points or -4.12 percent at $1.63 with a heavy trade volume of 1.798 million shares. After opening the session at $1.7, the shares went as high as $1.78 and as low as $1.58, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $97.05 million and now has 59.54 million shares outstanding. Melinta Therapeutics, Inc. (MLNT) stock has gained 53.77 percent of market value in 21 trading days.
MLNT stock has a trailing 3-year beta of 2.05, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$4.31 a share in the trailing twelve months. The stock’s value has surged 105.63 percent year to date (YTD) against a decline of -86.64 percent in 12 month’s time. The company’s shares still trade -88.19 percent away from its 1-year high of $13.80 and 153.11 percent up from 52-week low of $0.64. The average consensus rating on the company is 1.8, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a buy.